On June 30, Lilly agreed to hand a Chinese partner full commercial control of one of its cancer drugs. The move looks minor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results